John Paulson’s Travere Therapeutics TVTX Stock Holding History

John Paulson’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-55,000	Closed	-$1.04M	–	113
2016 Q4	$1.04M	Buy	+55,000	New	+$1.12M	0.01%	91

Other funds holding TVTX

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

John Paulson's TVTX Position: Q1 2017 in Review

John Paulson sold out of Travere Therapeutics (TVTX) in Q1 2017, closing a stake of 55,000 shares — an estimated $1.04M sold.

John Paulson first reported a position in TVTX in Q4 2016 and held it in 1 quarter. The position peaked at $1.04M in Q4 2016. 114 funds tracked by Wall St. Rank hold TVTX as of Q1 2017.

John Paulson reported no remaining Travere Therapeutics position as of Q1 2017 after selling out during the quarter.
John Paulson sold 55,000 Travere Therapeutics shares in Q1 2017, an estimated $1.04M.
John Paulson first reported a position in Travere Therapeutics in Q4 2016 and held it in 1 quarter.
John Paulson's Travere Therapeutics position peaked at $1.04M in Q4 2016.
114 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2017.

Based on Paulson & Co's 13F filing for Q1 2017, filed 15 May 2017.